Intelligent Telehealth in Pharmacovigilance: A Future Perspective
Heba H Edreesa b c, Wenyu Songb c, Ania Syrowatkab c, Aurélien Simonab c, Mary G. Amatob, David Westfall Batesc d e f✉
- aDepartment of Pharmacy Practice, MCPHS University, Boston, MA, USA
- bDivision of General Internal Medicine, Brigham and Women's Hospital, Boston, MA, USA
- cHarvard Medical School, 1620 Tremont St., 3rd Floor, Boston, MA, 02120, USA
- dDepartment of Health Policy and Management, Harvard School of Public Health, Boston, MA, USA. dbates@bwh.harvard.edu
- eDivision of General Internal Medicine, Brigham and Women's Hospital, Boston, MA, USA. dbates@bwh.harvard.edu
- fHarvard Medical School, 1620 Tremont St., 3rd Floor, Boston, MA, 02120, USA. dbates@bwh.harvard.edu
- ✉Corresponding author
Papers open inside SciRah from the original publisher or repository; SciRah never hosts them.
Abstract
Pharmacovigilance improves patient safety by detecting and preventing adverse drug events. However, challenges exist that limit adverse drug event detection, resulting in many adverse drug events being underreported or inaccurately reported. One challenge includes having access to large data sets from various sources including electronic health records and wearable medical devices. Artificial intelligence, including machine learning methods, such as natural language processing and deep learning, can detect and extract information about adverse drug events, thus automating the pharmacovigilance process and improving the surveillance of known and documented adverse drug events. In addition, with the increased demand for telehealth services, for managing both acute and chronic diseases, artificial intelligence methods can play a role in detecting and preventing adverse drug events. In this review, we discuss two use cases of how artificial intelligence methods may be useful to improve the quality of pharmacovigilance and the role of artificial intelligence in telehealth practices.
TL;DRTwo use cases of how artificial intelligence methods may be useful to improve the quality of pharmacovigilance are discussed and the role of artificial intelligence in telehealth practices is discussed. (Semantic Scholar)